Validation of the psoriasis epidemiology screening tool (PEST) and the new early arthritis for psoriatic patients (EARP) in pediatric population: pilot study

2022 ◽  
Author(s):  
Hadar Gavra ◽  
Irit Tirosh ◽  
Shiri Spielman ◽  
Shoshana Greenberger ◽  
Gil Amarylio ◽  
...  
Keyword(s):  
Pilot Study ◽  
Screening Tool ◽  
Pediatric Population ◽  
Early Arthritis

scholarly journals OP0305 VALIDATION OF THE PSORIASIS EPIDEMIOLOGY SCREENING TOOL (PEST) AND THE NEW EARLY ARTHRITIS FOR PSORIATIC PATIENTS (EARP) IN PEDIATRIC POPULATION - PILOT STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 187.2-187
Author(s):  
Y. Butbul
Keyword(s):  
Psoriatic Arthritis ◽  
Sensitivity And Specificity ◽  
Pediatric Patients ◽  
Screening Tool ◽  
Pediatric Population ◽  
Joint Damage ◽  
High Sensitivity ◽  
Early Arthritis ◽  
Screening Tools ◽  
Questionnaire Score

Background:Juvenile Psoriatic Arthritis (JPsA) is an inflammatory arthritis associated with irreversible joint damage among the pediatric population, which is associated with psoriasis in most cases.While there are few validated screening tools for diagnosis of arthritis for adult patients with psoriasis, those screening tools were never evaluated in children.Objectives:The aims of this study were to evaluate two screening tools among pediatric patients with psoriasis.Methods:Thirty-nine patients with the diagnosis of psoriasis were administered two screening questionnaires: the new Early Arthritis for Psoriatic Patients (EARP) questionnaire and the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire.All patients were evaluated by a rheumatologist for the diagnosis of JPsA, and the accuracy of the two questionnaires compared.Results:The 4/39 (10.1%) patients diagnosed with JPsA had a PEST questionnaire score of ≥ 3, compared to a median PEST score of the patients without the diagnosis of JPsA of 0 (0-2). Thus both the sensitivity and specificity of the PEST in diagnosing JPsA were 100%.For the EARP questionnaire, 8/39 patients had a screening questionnaire score of ≥ 3, suggestive of JPsA, four were true positive, and four false positive. Thus, the sensitivity and specificity of EARP in diagnosing JPsA were 100% and 89%, respectively.Conclusion:Both the PEST and EARP questionnaires were easy to use and had high sensitivity for pediatric population with psoriasis, however the PEST questionnaire had a higher specificity than the EARP.Disclosure of Interests:None declared.

scholarly journals Utility of Olfactory test as screening tool for COVID-19: A pilot study

2020 ◽  
Author(s):  
Pragyanshu Khare ◽  
Atul Munish Chander ◽  
Kanhaiya Agrawal ◽  
Satyam Singh Jayant ◽  
Soham Mukherjee ◽  
...  
Keyword(s):  
Pilot Study ◽  
Preliminary Data ◽  
Screening Test ◽  
Screening Tool ◽  
Healthy Controls ◽  
Olfactory Test ◽  
Smell Test ◽  
Variable Sensitivity ◽  
Novel Coronavirus ◽  
Smell Function

Loss of smell function (Anosmia) is reported to be associated with novel coronavirus disease 2019 (COVID-19) infection. The present study was designed to evaluate the effectiveness of an indigenously developed prototype smell test to identify/diagnose asymptomatic COVID-19 positive individuals. A panel of five different odorants belonging to Indian household with unique and mutually exclusive odor were used to develop prototype kit to test the hypothesis. The developed prototype kit was tested at 2 centers (N=49 and 34) with slight modifications. Simultaneously, the kit was also tested on 55 (N=35 and 20) healthy controls. Our results indicate that otherwise asymptomatic COVID-19 positive individuals were having quantifiable deficit in smell sensation. Interestingly, the variable sensitivity of different odorants was observed in different patients. None of the healthy controls reported difficulty in sensing any of the odorant, whereas, some of healthy controls did misidentify the odorants. Overall, the present study provides a preliminary data that loss in smell sensation for various odorants can be exploited as a quick and affordable screening test to identify infected cases among at risk individuals.

The role of G8 screening tool in the assessment of surgical outcome of elderly patients (≥ 75 y.o.) with kidney tumours: A pilot study

2017 ◽  
Vol 16 (3) ◽  
pp. e1180
Author(s):  
T. Silvestri ◽  
N. Pavan ◽  
G. Chiapparrone ◽  
F. Vedovo ◽  
G. Di Cosmo ◽  
...  
Keyword(s):  
Pilot Study ◽  
Elderly Patients ◽  
Surgical Outcome ◽  
Screening Tool ◽  
G8 Screening Tool

scholarly journals Pilot study: Decreasing parental anxiety during peanut oral immunotherapy

2019 ◽  
Vol 10 (3) ◽  
pp. 65
Author(s):  
Kinga P. Olson ◽  
Ruth Rosenblum
Keyword(s):  
Pilot Study ◽  
Pediatric Population ◽  
Oral Immunotherapy ◽  
Careful Consideration ◽  
Food Allergies ◽  
Children And Families ◽  
Convenience Sample ◽  
Parent Survey ◽  
Parents And Children ◽  
Fda Approval

Objective: Peanut allergies are common in the pediatric population. Peanut oral immunotherapy (OIT) can cause anxiety for children and families. A pilot study was conducted to determine what elements parents consider most useful in reducing anxiety within a newly implemented OIT program.Methods: A convenience sample of parents (n = 15) was surveyed to measure perceptions of specific anxiety-reducing elements at a private allergy practice.Results: The 10-question parent survey utilized a Likert Scale measuring how various elements of the OIT program reduced their anxiety. All elements that were provided directly by the clinic received favorable ratings.Discussion and conclusions: Commercially prepared peanut OIT will soon receive FDA approval, and allergy clinics will consider implementing this new therapy for peanut allergic patients. Food allergies invariably cause anxiety for parents and children, therefore careful consideration of how to decrease anxiety during OIT therapy was examined in this pilot study.

Testing for ‘threads’ and leucocyte esterase in first-void urine to exclude the diagnosis of non-specific urethritis in asymptomatic men

Sexual Health ◽  
2014 ◽  
Vol 11 (3) ◽  
pp. 283
Author(s):  
Sanjeeva N. S. Pallawela ◽  
Christopher Sonnex ◽  
Julia Burdett ◽  
Dawn Cooper ◽  
Katrina Nethercott ◽  
...  
Keyword(s):  
Pilot Study ◽  
Chlamydia Trachomatis ◽  
Confidence Interval ◽  
Neisseria Gonorrhoeae ◽  
Positive Predictive Value ◽  
Predictive Value ◽  
Incidental Findings ◽  
Screening Tool ◽  
Clinically Significant ◽  
Asymptomatic Men

Recent evidence suggests that asymptomatic nonspecific urethritis (NSU), which is not routinely tested for, is a clinically significant pathology.The aim of this pilot study was to determine if testing for urinary threads, leucocyte esterase (LE) or both in asymptomatic men is a good screening tool for NSU. Of the126 asymptomatic men, 8% met microscopic criteria for the diagnosis of NSU. The positive predictive value for NSU was 71% (95% confidence interval (CI): 29.3–95.5%) and the negative predictive value was 96% (95% CI: 92.8–99.5%). The absence of threads and negative LE makes urethritis highly unlikely, making urinary chlamydia (Chlamydia trachomatis) and gonorrhoea (Neisseria gonorrhoeae) testing sufficient. Incidental findings of further pathology occurred in 7%.

Once-Daily Enoxaparin for the Treatment of Pediatric Thromboembolic Disease — A Pilot Study.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 880-880
Author(s):  
Sarah O’Brien ◽  
Arthur K. Ritchey
Keyword(s):  
Ischemic Stroke ◽  
Pilot Study ◽  
Pediatric Population ◽  
Central Venous Line ◽  
Arterial Ischemic Stroke ◽  
Final Dose ◽  
Once Daily ◽  
Patients Âgés ◽  
Long Term Treatment ◽  
Starting Dose

Abstract Background & Aim: The current recommended starting dose of enoxaparin in children is 1 mg/kg/dose administered twice-daily. Studies in adults, however, have demonstrated similar safety and efficacy between once-daily enoxaparin (1.5 mg/kg/dose) and twice-daily (1 mg/kg/dose) in the initial and long-term treatment of venous thromboembolism. Due to known differences in heparin clearance between adults and young children, recommendations for once-daily enoxaparin dosing should not simply be extrapolated from adult literature. Our objective was to perform a pilot study to describe the pharmacodynamics of once-daily enoxaparin in children, and to gather preliminary data regarding safety and feasibility. Methods: 15 patients, ages 3 months to 16 years, with newly diagnosed thromboembolism were enrolled. All began therapy with 1.5 mg/kg enoxaparin administered once-daily. Initial peak anti-Xa levels were drawn 4–6 hours after the second dose of enoxaparin. Dose adjustments were made according to a study nomogram to achieve peak anti-Xa levels between 1–2 U/ml, as recommended by the American College of Pathologists for once-daily enoxaparin dosing. Once therapeutic levels were achieved, a subgroup of 8 patients underwent 24–hour pharmacodynamic (PD) monitoring, with anti-Xa levels drawn at Hours 0, 2, 4, 8, 12, 18, and 24. Results: 14 patients completed the study. 8 of 14 children required a final dose of >2 mg/kg to achieve target peak anti-Xa levels (Table). Only one participant (age 15 years) achieved target levels with the original dose. In PD studies, 7 of 8 children had subtherapeutic anti-Xa levels by Hour 12, and 4 of 8 had unmeasurable levels by Hour 18 (Figure). These results differ from adult studies in which therapeutic levels (0.5–1.0 U/ml) have been measurable 13–18 hours after administration, and prophylactic levels (0.1–0.3 U/ml) have been measurable at 24 hours. There were no new or recurrent thrombotic events. One patient was removed from the study on Day 2 because anticoagulation was permanently discontinued after a post-surgical bleed (anti-Xa 0.23 at time of event). Conclusion: Our pilot data suggests faster clearance of once-daily enoxaparin in the pediatric population as compared to adults. The appropriate starting dose of once-daily enoxaparin in young pediatric patients is likely higher than 1.5 mg/kg. Dose adjustments needed to achieve target peak anti-Xa activity (1–2 IU/ml) Patient Age Weight (kg) Indication for enoxaparin Dose changes Final dose (mg/kg) DVT, deep venous thrombosis; CVL, central venous line 1 3 months 6.5 DVT with CVL 4 3.8 2 10 months 10 DVT with CVL 4 4 3 14 months 13 DVT with CVL 2 2.3 4 2 years 14 DVT with CVL 4 2.7 5 3 years 14 DVT 2 2.7 6 8 years 83 DVT with CVL 1 1.7 7 9 years 37 Arterial ischemic stroke 1 1.9 8 13 years 67 DVT with CVL 2 2.1 9 14 years 65 DVT with CVL 2 2.2 10 14 years 68 DVT 1 1.8 11 15 years 60 DVT with CVL 1 1.9 12 15 years 60 Arterial ischemic stroke 1 1.6 13 15 years 77 DVT with CVL 0 1.5 14 16 years 45 DVT 3 2.9 Figure Figure

Developing the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire

2016 ◽  
Vol 36 (10) ◽  
pp. 1459-1468 ◽  
Author(s):  
Praveena Chiowchanwisawakit ◽  
Luksame Wattanamongkolsil ◽  
Varalak Srinonprasert ◽  
Chonachan Petcharat ◽  
Palanan Siriwanarangsun ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Screening Tool ◽  
Early Arthritis

Implementing a screening tool to improve prescribing in hospitalized older patients: a pilot study

2017 ◽  
Vol 40 (1) ◽  
pp. 15-19 ◽  
Author(s):  
Anne-Laure Sennesael ◽  
Olivia Dalleur ◽  
Séverine Henrard ◽  
Charline Artoisenet ◽  
Didier Schoevaerdts ◽  
...  
Keyword(s):  
Pilot Study ◽  
Older Patients ◽  
Screening Tool
Sign in / Sign up

Export Citation Format

Share Document